Board of Directors
Arthur Przybyl - Chief Executive Officer, ANI Pharmaceuticals
Arthur is an experienced healthcare executive with a career that spans over twenty-five years and includes the management of both specialty pharmaceutical and medical device companies. He joined ANI in March 2009 as President and CEO. Previously, Arthur was the President and CEO of Akorn, Inc., a NASDAQ specialty pharmaceutical company that manufactures and markets ophthalmic, liquid and lyophilized injectable, and vaccine drug products. Prior to Akorn, he was the President of privately held Hearing Innovations, Inc. and the President and COO of a NASDAQ company, Bioject, Inc., both medical device companies. During his career, Arthur has held several sales and marketing management positions, including Sr. V.P. Sales and Marketing for International Medication Systems, Inc. and Director Corporate Marketing and National Accounts for LyphoMed, Inc., both specialty pharmaceutical companies.
Arthur Kuan - Interim Chief Executive Officer
Arthur currently serves as Interim Chief Executive Officer and Director on the Board at Cold Genesys, a privately-held, clinical-stage biopharmaceutical company focused on the research, acquisition and development of novel immunotherapies, including an oncolytic virus for the treatment of bladder cancer and a variety of other solid tumor types. Arthur is a Founding Member of Ally Bridge Group, a global healthcare-focused investment platform, and plays an active role in managing the fund’s portfolio companies. Previously, Arthur was a member of Themes Investment Partners, a Private Equity fund based in Hong Kong, where he played a central role in coordinating cross-border technology transfer and regulatory submissions for portfolio companies. He began his career in an operational role at Dinova Capital, a Shanghai-based, medical technology incubator fund, evaluating medical device investment opportunities. Arthur received his M.S. in Biotechnology from the Johns Hopkins University and his B.A. in Biology from the University of Pennsylvania.
Krisztina Zsebo, Ph.D. - President, Biovest Consulting
Kris is a biopharmaceutical veteran with 33 years of experience in the Biotechnology industry, Kris has been involved in numerous successful ventures. Currently she is consulting for the biotechnology industry and heading up gene therapy R&D at Theragene Pharmaceuticals. She was CEO & President of Celladon Corporation, whereas the founding CEO for 11 years, she took the company public. While at Celladon, she led a team of researchers who took a basic research project through to Phase 2b clinical trials. She was also an Entrepreneur in Residence at Enterprise Partners Venture Capital. Prior to joining Enterprise, she was CEO & President of Remedyne. Before coming to Remedyne she was EVP of Connetics Corporation.
Kris also headed the Biopharmaceutical and Implant Division of ALZA Corporation, where she was responsible for the division which developed and filed the NDA for Viadur®, an implantable drug/device for prostate cancer patients. At Cell Genesys, where she was EVP of Research and Product Development, she was responsible for filing their first IND for a gene therapy product for AIDS. She also managed the Xenotech division, which was spun off to become Abgenix, one of the most successful biotech companies. Earlier in her career, Kris spent eight years at Amgen in research and product development where she worked on the discovery of NEUPOGEN®, as well as Stem Cell Factor, and various aspects of EPOGEN® development.
Kris received a B.S. in Biochemistry from the University of Maryland, a M.S. in Biochemistry and Biophysics from Oregon State University and a Ph.D. in Comparative Biochemistry and Molecular Biology from the University of California, Berkeley. She has published over 100 articles on biotechnology and holds 21 patents in the biotech field.
Luke Li, M.D. - Managing Director, Ally Bridge Group
Luke has 30 years of experience in biopharma and healthcare business. Currently, he is a Managing Director at Ally Bridge Group (“ABG”), a global healthcare investment platform, where he oversees biopharma investment opportunities for the healthcare fund and plays an important role in guiding science and business development for ABG’s portfolio companies. Before joining ABG, Luke was an Executive Director and the Head of Global Biotherapeutics, External R&D Innovation at Pfizer from 2010 to 2015, where he led search and evaluation as well as business development for in-licensing of innovative assets and cutting-edge technologies. He focused on Oncology, Biotechnologies, Pharmaceutical Sciences as well as Biosimilars to strengthen Pfizer’s pipeline. Luke served as Amgen’s Executive Director from 1993 to 2009, leading discovery research to IND, in which he advanced more than 3 dozen biologics into development, including several marketed products. From 1986 to 1992, Luke completed his fellowship training in Hematology/Oncology, and then became an Assistant Professor in Medicine at Washington University Medical School. Luke earned his M.D. from Fujian Medical University.
Ronald Cheng - Managing Director, Wellchamp Capital
Ronald has more than 20 years of experience in the Finance and Investment realm with an emphasis in media and biotechnology. He is the Founder and Managing Director at Wellchamp Capital Limited, a Hong Kong SFC registered asset management and investment advisory firm. In 2002, Ronald was Investor and Director of Plasmagene Bioscience, a biotechnology company founded by Dr. Alex Yeung, which eventually became listed as a part of the Hong Kong Stock Exchange (SEHK). Ronald was also Investor and Director of New Media Corp, a telecommunications media company invested in news and publication since 1975. Ronald holds a B.S. from The Chinese University of Hong Kong in Business Administration.
Simone Song - Senior Partner, ORI Capital
Simone is the Senior Partner of ORI Capital, a healthcare focused venture fund. She has more than 20 years of experience in corporate finance, she was most recently a Managing Director in the Investment Banking Division of Goldman Sachs, responsible for its healthcare activities in Greater China and was involved in a broad range of strategic advisory and financing transactions for healthcare clients. Simone holds a B.A. in Economics from Fudan University and a M.A. in Economics from Claremont Graduate School.
Paul DeRidder, M.D. - Co-Founder
Paul is a physician and surgeon, a California board certified urologist, with a specialty of Adult Urology. He was Assistant Clinical Professor of Urology in the Department of Surgery, at the University of California, Irvine School of Medicine (1979-2004). At St. Joseph Hospital in Orange, California, he served as Chairman of the Section of Urology 1981-1983, Vice-Chairman of the Dept. of Surgery, 1990, and Member of the Executive Committee 1991-1993. Paul served as Medical Director, Lithotripsy Services from 1989-1998, where he was tasked with acquisition of a $2M surgical kidney stone device. He is a Diplomate of The American College of Physician Executives. Paul was a co-founder, served as Chief Medical Officer, and a Board member of Urotherapies, Inc., a nationally based single specialty management group dedicated to the enhancement of urologic specialty care (1997-2000). He served on the Executive Committee of the Corporate Partners Program at the University of California, Irvine, Paul Merage School of Business (2000-2005) and was also a member of the Executive Committee, and Charter Member of UCI’s Business School Dean’s Leadership Circle (2005-2006). Paul is a co-Founder and formerly Chief Medical Officer of Cold Genesys. He was instrumental in contracting a “spin-out” of this technology from BioSante Pharmaceuticals, and obtaining angel investor financing to bring the technology back into clinical testing.